Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants

Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2013, Pages 21-28

  Yin, Donghua ^a   Sleight, Barbara ^a   Alvey, Christine ^a   Hansson, Arne G ^a   Bello, Akintunde ^a  

^a PFIZER INC   (United States)

Author keywords

Figitumumab; IGF 1 receptor; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBOPLATIN; FIGITUMUMAB; IMMUNOGLOBULIN G2; PACLITAXEL; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CONJUNCTIVAL HYPEREMIA; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRY EYE; EWING SARCOMA; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERURICEMIA; IMMUNOGENICITY; INSULIN BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PROTEIN BLOOD LEVEL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD GLUCOSE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; YOUNG ADULT;

EID: 84877855878     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011432934     Document Type: Article

References (22)

1. Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. . 2003;69:257-271.
2. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. . 2003;13:113-170.
3. Cohen P. Overview of the IGF-I system. . 2006;65(suppl 1):3-8.
4. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. . 2008;14:6364-6370.
5. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. . 2008;8:915-928.
6. Romano G. The complex biology of the receptor for the insulin-like growth factor-1. . 2003;16:525-531.
7. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. . 2005;35:24-34.
8. Mohamed-Ali V, Pinkney J. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus. . 2002;1:399-410.
9. Abbas A, Grant PJ, Kearney MT. Role of IGF-1 in glucose regulation and cardiovascular disease. . 2008;6:1135-1149.
10. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. . 2005;11:2063-2073.
11. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. . 2008;26:3196-3203.
12. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. . 2007;13:5834-5840.
13. Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. . 2010;103:332-339.
14. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. . 2010;11:129-135.
15. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. . 2009;4:1397-1403.
16. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with nonsmall cell lung cancer (NSCLC). . 2010;28:Abstract 7500.
17. Gualberto A, Dolled-Filhart M, Gustavson M, et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. . 2010;16:4654-4665.
18. Gualberto A, Hixon ML, Karp DD, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. . 2011;104:68-74.
19. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. . 2010;65:765-773.
20. Mizuno N, Kato Y, Iwamoto M, et al. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. . 2001;18:1203-1209.
21. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. . 2009;30:417-437.
22. Holt RI, Simpson HL, Sönksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. . 2003;20:3-15.